Active Surveillance for Intermediate Risk Prostate Cancer

Area of Science:

• Urology
• Oncology
• Medical Surveillance

Background:

• Active surveillance (AS) is standard for low-risk prostate cancer (PCa).
• Its application in intermediate-risk PCa remains debated, with exclusions based on factors like Gleason score, PSA levels, age, and race.
• Current guidelines often exclude men with Gleason 3+4 disease, PSA >10, younger age, or African-American ethnicity from AS.

Purpose of the Study:

• To evaluate the efficacy and safety of active surveillance for intermediate-risk prostate cancer.
• To identify factors influencing outcomes in men with intermediate-risk PCa managed with AS.
• To inform personalized risk assessment and treatment decisions for this patient group.

Main Methods:

• Review of outcome data for intermediate-risk PCa patients managed with AS.
• Analysis of the impact of specific risk factors (Gleason score, PSA, age, race) on disease progression.
• Assessment of emerging tools like biomarkers and multiparametric MRI for risk stratification.

Main Results:

• Intermediate-risk PCa patients on AS have reasonable outcomes but an elevated risk of metastatic progression.
• Younger age does not appear to negatively impact outcomes in AS, based on long-term follow-up.
• African-American men face higher risks of occult higher-grade disease, but favorable outcomes otherwise.
• Exclusion from AS should not be based on a single criterion; a multifactorial approach is necessary.

Conclusions:

• Active surveillance can be a safe approach for carefully selected intermediate-risk prostate cancer patients.
• Personalized risk assessment integrating clinical data, imaging (MRI), and biomarkers is crucial.
• Treatment decisions for intermediate-risk PCa should consider a comprehensive set of parameters, not single risk factors.